Effect of hepatic or renal impairment on eltrombopag pharmacokinetics

Journal of Clinical Pharmacology

Volumn 51, Issue 5, 2011, Pages 739-750

  Bauman, John W ^a   Vincent, Carolyn T ^a   Peng, Bin ^b   Wire, Mary B ^a   Williams, Daphne D ^c   Park, Jung Wook ^a  

^a GLAXOSMITHKLINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

eltrombopag; hepatic impairment; pharmacokinetics; renal impairment thrombocytopenia; safety

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ALLOPURINOL; ALPRAZOLAM; AMFEBUTAMONE; ATENOLOL; ATORVASTATIN; BILIRUBIN; CALCIUM; CLOPIDOGREL; CREATININE; DILTIAZEM; ELTROMBOPAG; ESOMEPRAZOLE; FLUOXETINE; FOLIC ACID; FUROSEMIDE; GLIPIZIDE; IBUPROFEN; LACTULOSE; LANSOPRAZOLE; METFORMIN; NADOLOL; NAPROXEN; PARACETAMOL; SALBUTAMOL; SPIRONOLACTONE; TRAZODONE; UNINDEXED DRUG; ZOLPIDEM;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DISEASE SEVERITY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; LIVER DISEASE; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MYALGIA; NAUSEA; OPEN STUDY; PARALLEL DESIGN; PHASE 1 CLINICAL TRIAL; PLASMA PROTEIN BINDING; QT PROLONGATION; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTE COUNT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; AGED; AREA UNDER CURVE; AUSTRALIA; BENZOIC ACIDS; DRUG DOSAGE CALCULATIONS; FEMALE; HALF-LIFE; HUMANS; HYDRAZINES; KIDNEY; KIDNEY DISEASES; LIVER; LIVER DISEASES; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; NEW ZEALAND; PYRAZOLES; RECEPTORS, THROMBOPOIETIN; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 79955543812     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010372106     Document Type: Article

References (17)

1. Jenkins JM, Williams D, Deng Y, et al. Phase I clinical study of eltrombopag, an oral, non-peptide thrombopoietin receptor agonist. Blood. 2007 ; 109: 4739-4741 (Pubitemid 46827766)
2. Kuter DJ. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Ann Rev Med. 2009 ; 60: 193-206
3. Erickson-Miller CL, Delorme E, Tian S, et al. Preclinical activity of eltrombopag (SB-497115), an oral, non-peptide thrombopoietin receptor agonist. Stem Cells. 2009 ; 27: 424-430
4. Research Triangle Park, NC: GlaxoSmithKline ; 2008 :
5. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenia purpura. N Engl J Med. 2007 ; 357: 2237-2247 (Pubitemid 350190754)
6. Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomized, double-blind, placebo-controlled trial. Lancet. 2009 ; 373: 641-648
7. McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007 ; 357: 227-2236
8. Zhang J, Williams DD, Moore KP. Use of eltrombopag exposure-platelet response relationship for dose optimization in patients with chronic HCV-infection with and without interferon. Presented at: 18th Population Approach Group in Europe (PAGE) ; St Petersburg, Russia;.
9. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973 ; 60: 646-649
10. Pichette V, Leblond FA. Drug metabolism in chronic renal failure. Curr Drug Metab. 2003 ; 4: 91-103 (Pubitemid 36443190)
11. Forge ST, Phillips DL, Bedding AW, et al. Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics. Br J Clin Pharmacol. 2006 ; 63: 24-35 (Pubitemid 44902874)
12. De Martin S, Orlando R, Bertoli M, Pegoraro P, Palatini P. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis. Clin Pharmacol Ther. 2006 ; 80: 597-606 (Pubitemid 44908268)
13. Dreisbach AW, Lertora JL. The effect of chronic renal failure on hepatic drug metabolism and drug disposition. Semin Dial. 2003 ; 16: 45-50 (Pubitemid 37356766)
14. Naud J, Michaud J, Leblond FA, Lefrancois S, Bonnardeaux A, Pichette V. Effects of chronic renal failure on liver drug transporters. Drug Metab Dispos. 2008 ; 36: 124-128
15. Naud J, Michaud J, Boisvert C, et al. Down-regulation of intestinal drug transporters in chronic renal failure in rats. J Pharmacol Exp Ther. 2007 ; 320: 978-985 (Pubitemid 46294060)
16. Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S. Drug protein binding in chronic renal failure: evaluation of nine drugs. Kidney Int. 1988 ; 33: 996-1004
17. Williams DD, Peng B, Bailey CK, et al. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. Clin Ther. 2009 ; 31: 764-776